CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas By Ogkologos - July 16, 2026 164 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 10-year follow-up of a phase II study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR 什么是癌症的肿瘤标志物检测？您需要需要知道的 8 件事 June 24, 2021 FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell... May 24, 2024 Grabbing the Perfect Gift December 16, 2023 ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December December 2, 2024 Load more HOT NEWS Patient Guide in Testicular Cancer Now Available Also in German FDA Approves Margetuximab for Metastatic HER2-positive Breast Cancer EMA Recommends Extension of Therapeutic Indications for Epcoritamab ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΝΕΥΜΟΝΑ:ΝΕΑ ΜΕΛΕΤΗ, ΝΕΕΣ ΕΛΠΙΔΕΣ
